Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 73

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1
Chunk 73
---
ARCH 31, 2025 AND 2024

(Unaudited)

As
of March 31, 2025, options exercisable totaled 2,073,920. The Company recognized approximately $1.4 million in stock-based compensation
in the three months ended March 31, 2025. There is approximately $0.8 million of unrecognized compensation cost related to non-vested
share-based compensation awards, which will be expensed through 2026.

Note
7. Segment Information

The
Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neurologic and
neuropsychiatric disorders. The CODM for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO
reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial
performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure.
The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a
basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

The
accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies
within Note 1. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that
is also reported on the statement of operations as net loss. The measure of segment assets is reported on the balance sheets as total
assets.

The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

Schedule
of Segment Information

    Three
    Months Ended March 31, 

    2025  
    2024 
  
    Revenues 
    $—  
    $— 
  
    Less segment expenses: 

    Research and
    development 
     336,996  
     804,023 
  
    Related party travel costs 
     -  
     370,500 
  
    General
    and administrative 
     1,850,786  
     741,541 
  
    Loss
    from operations 
    $2,187,872  
     1,916,064 
  
    Plus: 

    Interest
    income (expense),net 
     7,954  
     (4,338,543